📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
4 articles
AVG GRADE
NEUTRAL
score: 0.38
SENTIMENT
NEUTRAL
TOTAL VIEWS
15
TENX Stock Analysis & AI Grade: NEUTRAL
4 articles analyzed · Sentiment: NEUTRAL · AI-powered equity research
RECENT COVERAGE · 4 ARTICLES
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow (NASDAQ:TENX) 2026-08-11
Tenax Therapeutics (TENX) released a slide deck presentation discussing Phase III LEVEL trial outcomes for its oral levosimendan...
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
TENX released a transcript discussing Phase III LEVEL trial results for oral levosimendan in heart failure with preserved ejection...
Tenax Therapeutics: Double Or Nothing (NASDAQ:TENX)
Tenax Therapeutics (TENX) faces a pivotal moment with Phase 3 LEVEL trial data on its oral levosimendan candidate. The binary nature of...
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics (TENX) disclosed Q2 2026 financial results alongside a near-term clinical inflection point, with Phase 3 LEVEL trial...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice